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Introduction
The primary goal in the surgical management of 
chronic otitis media with cholesteatoma is the com-
plete removal of squamous epithelium from the 
middle ear spaces and the creation of a dry and safe 
ear. Postoperatively, the ear should be easy to care 
and free of residual or recurrent cholesteatoma. The 
method of choice for the surgical management of 
middle ear cholesteatoma is following the matrix of 
cholesteatoma from anterior to posterior with par-
tial or total removal of posterior canal wall, the so 
called inside out canal wall down or reverse mas-
toidectomy. After complete cholesteatoma removal, 
partial or total mastoid cavity obliteration is consid-
ered if a posterior canal wall reconstruction is not 
possible. In rare cases of extensive or recurrent cho-
lesteatoma, a subtotal petrosectomy with closure of 
the Eustachian tube and external ear canal will be 
performed, completely isolating the mastoid cavity 
from the exterior. Hearing improvement is consid-
ered to be the secondary task of complex treatment 
of cholesteatoma.
The basic question when to use either closed (Ca-
nal Wall-Up, CWU) or open (Canal Wall-Down, 
CWD) technique existed not more. The criteria for 
selecting a technique for cholesteatoma surgery de-
scribed from Jahnke et al. we use to influence our 
decision for canal wall reconstruction or mastoid 
cavity obliteration (Table. 1) (1), equating indica-
tions for canal wall reconstruction to indications 
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surgeon. The decision for mastoid obliteration is in-
fluenced mainly by the school and routine, but also 
from the individual personality and sensitivity of 
the surgeon. Various materials are used, including 
autogenous bone and cartilage, free or vascularized 
soft tissue, and bioactive or biocompatible alloplas-
tic materials. Finally, the experience of the surgeon 
is decisive for the result of the entire surgical pro-
cedure.
The aim of this study is to present our current con-
cept of our Plester School for mastoid cavity oblit-
eration procedure. Middle ear cholesteatoma sur-
gery, based on techniques developed by Dietrich 
Plester and further developed by Jan Helms and 
Henning Hildmann, use standardized procedures 
called “Individualized Approach to Cholesteato-
ma Surgery” (8).We use this technique in routine 
practice over last 20 years, therefore the principles 
presented here are results of acquired surgical and 
clinical knowledge.
Methods
The here presented patient collective included 176 
cholesteatoma operations (38.85%) from 453 con-
secutive middle ear surgery for 4 years and 4 months 
in Trakia Park Hospital Stara Zagora, Bulgaria from 
01.06.2014 to 30.09.2018. This retrospective study 
describes 155 patients with congenital (4) and ac-
quired (151) cholesteatoma of the middle ear with 
age distribution from 4 to 76 years (mean age 35.8 
years; SD 18.0 years) and follow-up period from 1 
to 48 months (mean 11.34 months; SD 13.10) and 
female/male distribution 67 to 88; left ear 78, right 
ear 77. Preoperatively, the patients were evaluated 
according to the Bellucci Classification (n=176): 
Gr. 1/9 (5%), Gr. 2/37 (21%), Gr. 3/120 (68%), Gr. 
4/10 (6%). One surgeon performed 106 Primary 
Cholesteatoma Surgery (60.22%, n=176), 49 Revi-
sion Surgery (27.84%, n=176), previous operations 
in another hospital (x5/1; x4/2; x3/3; x2/6; x1/37) 
and 21 Second-Look Surgery (11.93%, n=176).
Mastoid cavity obliteration was performed in re-
vision but also in primary surgery. Biological and 
alloplastic obliteration materials were applied. Ho-
mologous materials are no longer allowed due to 
medicolegal reasons. Our material collection for 
mastoid obliteration technique included cartilage, 
bone or bone replacement alloplastic materials and 
soft tissue flaps.
Cartilage (large plates or palisades) is taking from 
cavum or cymba conchae or from tragus. Bone dust 
for close technique and equating indications for 
mastoid cavity obliteration to characteristics for 
open technique indications. A large mastoid, nor-
mal Eustachian tube function, young patients (who 
often require a staged procedure), and reliable af-
tercare are criteria for preserving or reconstructing 
the posterior canal wall. Recurrent cholesteatoma, 
a small mastoid, a prominent sinus, prolonged Eu-
stachian tube dysfunction, and uncertain aftercare 
are indications for creating an open mastoid cavity 
with obliteration. CWD surgery with primary oblit-
eration seems to be a safe and reliable one-staged 
procedure for the treatment of cholesteatoma in 
adults with poor mastoid pneumatization, which is 
associated with good clinical, functional and social 
long-term results (2). Before turning to partial or 
complete mastoid cavity obliteration, the surgeon 
must be certain that all cholesteatoma matrix have 
been removed. If there is the slightest doubt, the 
surgeon must create an open, small and self-clean-
ing cavity. Surgical measures for obtaining a small, 
self-cleaning cavity are lower the facial ridge to the 
level of the facial nerve; smooth all bony overhangs 
and cell septa with a diamond bur; if necessary, drill 
down the mastoid tip; reduce the sinus-dura angle 
by partial obliteration; widen the ear canal entrance 
by cartilage excision, additional anterior canal skin 
incision, and tacking the concha posteriorly (3).
First Mosher, 1911 use posterior musculo-periostal 
flap for partial mastoid cavity obliteration (4). Than 
Kisch, 1928 and Rambo, 1958 make total oblitera-
tion of the middle ear cleft after middle ear surgery 
with temporalis muscle (5). Palva, 1961 use ante-
rior musculo-periostal flap with tympanoplasty in 
combination with posterior canal wall reconstruc-
tion (6). We prefer to use cartilage and bone for 
mastoid obliteration. In recent days Bioactive glass 
S53P4 was used for frontal sinus obliteration. Sarin 
et al. first used Bioactive glass S53P4 for mastoid 
obliteration (7). We perform cavity obliteration in 
the first operation, but more often do it in revision 
surgery. If not indicated primarily, the obliteration 
can be performed in a second stage procedure, es-
pecially after several previous operations. Our pri-
mary goal of surgery is one-stage procedure if pos-
sible. The mastoid cavity obliteration can be partial 
or complete. Complete obliteration with abdominal 
fat and closure of the outer ear canal is rare proce-
dure.
The indications for and extent of obliterating mas-
toid air cells varies considerably from surgeon to 
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This is extremely important in cases of narrow 
ear canals. At this point of surgery we perform 
additional elevation of anterior canal skin and 
the remnants of anterior-superior part of tym-
panic membrane to allow a reconstruction with 
a cartilage in one plane at the end of the oper-
ation.
5. Following the matrix of cholesteatoma includ-
ing complete cholesteatoma removal from an-
terior to posterior with preservation of malleus 
handle and m. tensor tympani tendon if it is 
possible. The drill should not touch the epithe-
lium and should avoid spreading cholesteatoma 
particles. The bone has to be drilled down to 
the facial nerve, leaving it covered by thin layer 
of bone. Identify the position of the facial nerve 
at an early stage in the operation. Perineural 
vascular plexus is indirect landmark for the po-
sition of the facial nerve. Critical areas are S1 
and S2 from STAM System (16) – inspection 
with 30° otoendoscope. If the epithelium ex-
tends medially to the labyrinth, the treatment 
might require the destruction of the labyrinth.
6. Concha cartilage preparation with sufficient 
excision and ear canal enlargement with addi-
tional meatoplasty through outer meatal skin 
incision at about 12 and 6 o’clock. The flap is 
pulled backwards by subcutaneous sutures of 
the end of operation.
7. Tympanoplasty in combination with posteri-
or canal wall reconstruction with cartilage in 
cases with normal mastoid pneumatization. 
Partial or total defects of the posterior wall 
can be reconstructed, especially in cases that 
the cholesteatoma is small. Epitympanic space 
also should be reconstructed by cartilage. Car-
tilages must fit exactly one another.
8. Tympanoplasty in combination with mastoid 
cavity obliteration with bone and cartilage in 
poor mastoid pneumatization or if posterior ca-
nal wall reconstruction is not possible. Mastoid 
cavity obliteration cut be done after certain re-
moval of all epithelium from the mastoid. Fill 
the cavity adequately and the Bone Paté or 
nonbiological granules must be fully covered 
with cartilage or connective tissue.
9. Reimplantation of the removed meatal skin 
flap or split-thickness skin grafts from the 
postauricular region as a free graft and package 
closely the external ear canal with antibiotic 
filled Gelfoam after covered with silicone foil 
s. Bone Paté can be collected in a special glass ves-
sel (Collector) connected to the suction apparatus 
during drilling (9), or it may be harvested with a 
Jansen Raspatorium. We use this material to oblite-
rate the deepest areas located above and behind the 
lateral semicircular canal and after that we covered 
it with cartilage plates with overlapping perichon-
drium or connective tissue. When it is not possible 
to deliver Bone Paté,we use Bioactive or biocom-
patible alloplastic materials, for example Bioactive 
glass S53P4 (silicone dioxide, SiO2 53%; disodium 
oxide, Na2O 23%; calcium oxide, CaO 20% and 
phosphate pentoxide, P2O5 4%/) (10, 11).These 
materials even more categorically must be covered 
with connective tissue flaps, perichondrium or car-
tilage to keep in place and to induce new bone for-
mation. Some authors suggest fibrin glue, platelet 
reach plasma or similar materials to cover the oblit-
erated area (12, 13).
Soft tissue flaps as material for mastoid obliteration 
included Palva muscle-periosteal posterior flap or 
inferior musculo-fascial pedicle flap. For example 
M. Tos associated mastoid obliteration with Pal-
va flap and there modifications (14). Paparella et 
all. also described inferior musculo-fascial pedicle 
from behind the ear as more commonly employed 
method of mastoid obliteration (15).
The personal experience of the surgeon influences 
the techniques that are preferred in any given case 
of cholesteatoma. Our treatment concepts define 
clearly surgical principles in our operative protocol 
and individual surgical steps:
1. Periauricular local anesthesia with Lidocain + 
Adrenalin, 1:100,000 before surgery.
2. Retroauricular approach allows extensive ex-
posure of the mastoid according to the extent of 
the disease and of the end of operation allows 
better view in anterior tympanomeatal angle 
area. Only for smaller cholesteatoma not ex-
tending into the mastoid is the endaural or en-
domeatal approach preferable. When perform-
ing retroauricular incision of posterior canal 
skin the lateral canal skin must be preserved.
3. Carefully preparation and removal of the 
meatal skin flap and re-implant it at the end of 
the operation as a free graft. This allows more 
space for drilling and prevents damage of the 
skin flap by the drilling. Additionally it im-
proves the overview and saves time.
4. Enlargement of external auditory canal with 
posterior bone drilling with bone collection. 
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46.45% (72; n=155). Canal reconstruction we did in 
51.61% of cases (80; n=155), mastoid cavity oblite-
ration – in 41.94% of cases (65; n=155). From this 
65 cases of mastoid cavity obliteration we have 1/3 
obliteration, on the level of facial nerve, in 20 cases 
(30.77%), 2/3 obliteration – in 23 cases (35.38%) 
and 3/3 full obliteration – in 22 cases (33.85%). In 
our cases we used cartilage (Fig. 1), Bone Paté (Fig. 
2) and Bioactive glass S53P4 (Fig. 3). The distribu-
tion of this we show on Table 2.
In 56 from 155 operation we have intraoperative 
indication for second-look surgery (36.13%). For 
study period we make only 21 second-look opera-
tions (14%, n = 155). In 9 from this 21 second-look 
operation (42.86%) we found residual cholesteato-
ma in the following localizations: T/1, S2/1, A/3, 
S1/4. In 3 from this 9 residual cases we indicat-
ed a “new second-look” tympanomastoidectomy 
(14.29%, n=21) 18 months following the first sec-
ond-look operation. Another 6 small residual pearl 
cholesteatoma were complete removal. Also resid-
ual rate in our study group is 9.03% (14; n=155). 
Only in 5 cases (3.23%, n=155) of the end of oper-
ation we establish residual cholesteatoma and leave 
the cavity open. Three from these 5 cases are revi-
sion surgery – we leave residual cholesteatoma near 
uncovered facial nerve in S1/S2 region.
Preoperative and postoperative ABG in our pa-
tients is 35,51 (SD 15,76) and 32,90 (SD 19,06), 
respectively, that it is significant improvement 
(p=0.03662). Additionally to our 72 stapes columel-
la tympanoplasty in 11 second-look cases (57.14%, 
n=21) we perform 10 TORP (length 3.0÷4.75 
mm; mean 3.68; SD 0.57) and 1 PORP (length 2.5 
mm) tympanoplasty. Preoperative and postopera-
tive ABG in this TORP/PORP group is 45,00 (SD 
12,25) and 17,73 (SD 5,64), respectively, that it is 
significant improvement (p=0.02213). Against the 
background of this hearing improvement, we only 
have complications in 17 cases (10,97%; n=155), 
which we show on Table 3. Our frequency of post-
operative ear secretion including infection and 
granulation is 6.45% (10; n=155).
Discussions
A closed technique requires that the posterior wall 
of the ear canal is preserved or reconstructed, and 
an aerated antrum is present behind the canal wall 
(8). This ensures that the middle ear cavity has an 
approximately normal depth and pneumatization. 
All other middle ear conditions are considered to be 
or cigarettes paper.
10. Periosteal, subcutaneous and skin sutures ret-
roauricular. The periosteal suture should pre-
vent stenosis of the external auditory canal, 
and the subcutaneous suture – the outstanding 
of the auricle.
11. Compressive dressing for 2 days incl. con-
trolled bone-conductive audiogram on first 
postoperative day.
12. Tamponed external auditory canal for 21 days 
incl. Ciprofloxacin 2 x 750 mg. for 5 or 2 x 500 
mg. for 10 days p.o. Alternative in children: 
amoxicillin and clavulanate potassium.
13. Postoperative control: regular examination 
and audiogram on 1, 3, 6 month postop., and 
then every year or MRI especially Diffu-
sion-Weighted Imaging with Turbo-Spin Echo 
2–3 years after surgery in instable ears or 5 
years in stable ears has been found to be of high 
sensitivity and specificity in diagnosing residu-
al or reccurent cholesteatoma (17, 18, 19).
14. Second-look surgery 12 (in children) or 18 
month (in adults) after surgery when intraoper-
atively indicated.
Results
According to STAM System (16) our patients di-
vided to the following localizations: T/80; A/99; 
M/67; S1/27; S2/38 with extra- and intra-cranial 
complications: dehiscence of the canal of the facial 
nerve in 31 cases; lateral semicircular canal fistu-
las type I in 13 cases; defect of the tegmen with 
exposed dura (21 cases) or of the sinus sigmoideus 
(5 cases) that does not require repair and are not 
coded as intracranial complications; defect of the 
tegmen with otoliquorrhoe and repair (2 cases) or 
sinus thrombosis (1 case) are coded as intracrani-
al complications. The staging according to same 
system are: I/71 (45,81%); II/41 (26,45%); III/40 
(25,81%); IV/3 (1.94%).
According to Austin-Kartush classification (20) we 
found: Malleus handle is present in 62.58% of cas-
es (97; n=155); Incus is preserve in only 1.94% of 
cases (3; n=155); Stapes superstructures is present 
in 56.13% of cases (87; n=155); Stapes footplate is 
present in 43.87% of cases (68; n=155), that cor-
responding to different groups: 0/3 (1.94%), A/67 
(43.23%), B/27 (17.42%), C/17 (10.97%), D/37 
(23.87%), F/4 (2.58%).
In our patient group we did type I tympanoplasty in 
36.77% (57; n=155) and type III tympanoplasty in 
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that if the stapes superstructure was absent, there 
was a greater potential for FND. Hence, otolog-
ic surgeons should carefully dissect neighboring 
structures of the facial canal during mastoidecto-
my, particularly if there is preoperative CT Scan 
evidence of damage to the stapedial superstructure. 
Another important point for postoperative hearing 
status is unsecure stapes footplate (27). For exam-
ple fractures of the stapes footplate or in cases in 
which the footplate is partially of fully absent or 
stapes luxation during surgery.
In 67 cases (43.23%, n=155) we found mastoid 
involvement of cholesteatoma, that define mi-
croscopic surgery. Endoscopic ear surgery can be 
performed in the remainder of cases. Modern sur-
gical approaches include open and closed cavities 
performed with or without obliteration techniques, 
and these approaches can be accomplished using a 
microscope, endoscope, or a combination of both 
(28).
Conclusions
The mastoid cavity and epitympanic obliteration 
procedure prevent development of postoperative 
retraction pockets and isolating the tympanum from 
the attic and mastoid and in this way is a safe and 
effective technique for the rehabilitation of CWD 
mastoidectomies. It is very well tolerated from 
the patients and recommend not only for revision 
surgery, but also for initial surgical management. 
In cases with mastoid cavity obliteration open or 
closed technique should not be opposed anymore, 
and to be complementary each other. We call this an 
adapted technique for cholesteatoma surgery. Hear-
ing results of this technique is variable according to 
the involvement of the ossicles of the middle ear, 
but with the possibility of fitting a hearing aids or 
middle ear implants.
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open techniques with or without obliteration. The 
pathophysiological idea of mastoid cavity oblitera-
tion in cholesteatoma cases is a surgical reduction of 
mucosal surface for gas exchange resulting to sur-
gical adaptation of the middle ear pressure balance 
to the limited outer gas supply due to prolonged ET 
dysfunction, thus lowering the recurrence rate and 
improving long-term surgical outcome (21).
The cholesteatoma has to be completely exposed 
during the surgical procedure. Only 4% from resid-
ual cholesteatoma is in mastoid area (22). Critical 
areas for complete cholesteatoma removal are ante-
rior epitympanum (S1) and sinus tympani posterior 
(S2). Inspection with 30° otoendoscope is useful. 
According to M. Tarabichi, 1997 in all choleseta-
toma cases intraoperative, the mastoid cavity must 
be inspected endoscopically (23). In most cases 
residual cholesteatoma are in S2 area, that’s why 
we use an otoendosope to identifying it in facial 
recesses. Recurrent cholesteatoma refers to a re-
traction pocket and must be differentiated from 
residual cholesteatoma. The causes, prevention 
and treatment are different. Recurrent cholesteato-
ma was detected in 5% (24). The mastoid cavity 
obliteration is designed to prevent development of 
postoperative retraction pockets by obliterating the 
mastoid cavity and isolating the tympanum from 
the mastoid. Extended cholesteatoma in combina-
tion with extended mastoid pneumatisation is an-
other important point of interest. In this challeng-
ing cases canal wall down obliteration technique is 
operative method of choice, using Bioactive glass 
S53P4, which we cover with Bone Paté. The Bone 
Paté in over 75% of patients will lead to osteoneo-
genesis, achieving in 2–3months (25).
Twelve months for postoperative follow-up is the 
minimum period to estimate the otorrhea and hear-
ing outcomes (26). We follow-up our patients from 
1 to 48 months (mean 11.34 months; SD 13.10 
months). Tympanic membrane shrinking with re-
traction pocket is a sign for long term follow up. 
For hearing reconstruction, PORP and TORP are 
used in a primary or staged setting. We have bet-
ter results in the cases of two stage operation with 
TORP and PORP insertion on second-look opera-
tion. For prevention of TORP luxation we increase 
the measured length with 0.25 mm.
Patients with cholesteatoma was predisposed to fa-
cial nerve dysfunction (FND). Tympanic segment 
of facial nerve is frequently involved. We found 
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Table 1. Criteria for selecting a technique for cholesteatoma surgery (modified according to Jahnke K et al., 1985).
Closed technique Open technique
Middle ear cholesteatoma
Normal pneumatization Poor pneumatization
Normal tubal function Tubal dysfunction
Pediatric patient Elderly patient
Second look possible Poor compliance
Extend of  disease
Fig. 1. Intraoperative view – mastoid cavity obliteration with cartilage.
Fig. 2. Intraoperative view – mastoid cavity obliteration with Bone Paté.
Fig. 3. Intraoperative view – mastoid cavity obliteration with Bioactive glass S53P4.
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Table 2. Materials used for mastoid cavity obliteration.
65 Obliteration from 155 All Cholesteatoma Operation (41.94%)





39 Obliteration from 49 Revision Cholesteatoma Operation (79.59%)
Bone
Bone Paté 28





Bioactive glass S53P4 25%
-16 Cases (15 revision; 1 primary by congenital cholesteatoma)
-2÷4 ml (Mean 2.44; SD 0.57)
Table. 3. Complications after cholesteatoma surgery (follow-up  




Open vestibule with vertigo and SNHL (persistent) 6 (2)
Otoliquorrhoe requiring Reoperation 2
Temporally Facial Nerve Dysfunction 3
Some patient has two or three different complications (17; n=155); 1.29% has persistent complications (2; n=155).
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